Impressive shrinkage of a giant prolactinoma treated with cabergoline in a prepubescent girl. What now?

Neuroendocrinology Letters

Volumn 34, Issue 4, 2013, Pages 275-277

  Christoforidis, Athanasios ^a   Tsakalides, Christos ^a   Anastasiou, Athanasia ^b   Pavlaki, Antigoni ^a   Dimitriadou, Meropi ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Ippokration Hospital Thessaloniki   (Greece)

Author keywords

Cabergoline; Delayed puberty; Giant; Prepubescent; Prolactinoma

Indexed keywords

CABERGOLINE; ESTRADIOL; GONADOTROPIN; PROLACTIN;

ADOLESCENT; ARTICLE; CASE REPORT; CLINICAL FEATURE; FEMALE; GIANT PROLACTINOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREPUBERTY; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RARE DISEASE;

EID: 84880535776     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, et al. (2006). Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65: 265-273. (Pubitemid 44079693)
2. Cho EH, Lee SA, Chung JY, Koh EH, Cho YH, Kim JH, Kim CJ, Kim MS (2009). Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. J Korean Med Sci 24: 874-878.
3. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G (2003). Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349: 2023-2033. (Pubitemid 37448925)
4. Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C (2003). Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol (Oxf) 58: 662-670. (Pubitemid 36566810)
5. Dekkers OM, Lagro J, Burman P, Jorgensen JO, Romijn JA, Pereira AM (2010). Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95: 43-51.
6. Kharlip J, Salvatori R, Yenokyan G, Wand GS (2009). Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 94: 2428-2436.
7. Krassas GE, Pontikides N, Kaltsas T (1999). Giant prolactinoma presented as unilateral exophthalmos in a prepubertal boy: response to cabergoline. Horm Res 52: 45-48. (Pubitemid 30071929)
8. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA, Endocrine S (2011). Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96: 273-288.
9. Shimon I, Benbassat C, Hadani M (2007). Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 156: 225-231. (Pubitemid 46554517)
10. Shrivastava RK, Arginteanu MS, King WA, Post KD (2002). Giant prolactinomas: clinical management and long-term follow up. J Neurosurg 97: 299-306. (Pubitemid 34827329)